Skip to main content
. 2020 Jan 30;147(1):37–47. doi: 10.1007/s11060-019-03318-5

Table 1.

Positive biomarkers and mutated genes analysed by pyrosequencing, in situ hybridisation, IHC and NGS for G52 and G53 tumour samples

Pyrosequencing G52 Tumour G53 Tumour
Pyro SEQ-MGMT Unmethylated Unmethylated
In situ hybridisation
EGFR Positive Positive
IHC
EGFR Positive Positive
PTEN Positive Positive
TOPIIA Positive Positive
PGP Positive Positive
Next generation sequencing
PTEN Mutated Mutated
EGFR Mutated Mutated
MAP3KI Mutated Mutated
NTRKI Mutated Mutated
TP53 Wild-type Mutated